Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) EBT Margin (2020 - 2025)

Harmony Biosciences Holdings' EBT Margin history spans 6 years, with the latest figure at 16.72% for Q4 2025.

  • For Q4 2025, EBT Margin fell 1118.0% year-over-year to 16.72%; the TTM value through Dec 2025 reached 24.76%, down 207.0%, while the annual FY2025 figure was 24.76%, 207.0% down from the prior year.
  • EBT Margin for Q4 2025 was 16.72% at Harmony Biosciences Holdings, down from 28.18% in the prior quarter.
  • Across five years, EBT Margin topped out at 34.37% in Q4 2022 and bottomed at 13.03% in Q3 2021.
  • The 5-year median for EBT Margin is 27.36% (2022), against an average of 23.62%.
  • The largest annual shift saw EBT Margin surged 20703bps in 2021 before it plummeted -2030bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 26.83% in 2021, then grew by 28bps to 34.37% in 2022, then tumbled by -31bps to 23.57% in 2023, then grew by 18bps to 27.9% in 2024, then tumbled by -40bps to 16.72% in 2025.
  • Per Business Quant, the three most recent readings for HRMY's EBT Margin are 16.72% (Q4 2025), 28.18% (Q3 2025), and 24.76% (Q2 2025).